Uncategorised - European Medical Journal

pancreatic cancer

ctDNA Levels Correlate with Tumour Volume in Metastatic Pancreatic Cancer

A new study reveals circulating tumour DNA correlates with tumour volume in metastatic pancreatic cancer, particularly with liver metastases.

malaria vaccine

PfSPZ Malaria Vaccine: High Safety, Low Efficacy in Children

A phase 2 trial in Gabon showed that the PfSPZ malaria vaccine is safe in children aged 1–12 years but failed to prevent Plasmodium falciparum infection.

Two US flags

US pharma tariffs: Trump threatens 100% on imports

Donald Trump has threatened sweeping new trade measures on the pharma sector unless manufacturers commit to producing in the US.

Woman suffering with insomnia

Insomnia Linked to Higher Risk of Gastrointestinal Disorders

Discover a study revealing how insomnia raises the risk of GERD and IBS, with genetic evidence linking poor sleep to gastrointestinal health.

melanoma check

Melanoma Imaging Study Sheds Light on Immunotherapy

The study demonstrated that [99mTc]Tc-Tilmanocept could detect secondary lesions in patients with melanoma undergoing ICI treatment.

EDG-7500 in Hypertrophic Cardiomyopathy

Michelle Michels and Perry Elliott discuss the CIRRUS-HCM study of EDG-7500 in hypertrophic cardiomyopathy, highlighting clinical benefits…

supplements

Supplement Labels Overstate Heart Health Benefits, Study Finds

Survey finds supplement labels mislead consumers into thinking products prevent disease, prompting calls to tighten regulatory standards.

Survival Clues from Necrotising Lung Infections in Critical Care

Necrotising lung infections (NLI) significantly affect the course and outcomes of patients requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).

Exploring the Effect of Parkinson’s Therapies on Vision

Visual symptoms in Parkinson’s disease may remain largely unchanged despite treatment with levodopa or deep brain stimulation.

Folinic Acid Combination May Help Extend Options in Pancreatic Cancer

Patients with unresectable pancreatic cancer who receive second-line treatment with nanoliposomal irinotecan in combination with fluorouracil and folinic acid may remain eligible for subsequent third-line chemotherapy.